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Background: In recent decades, melanoma incidence has been increasing in European countries; in 2006, there
were approximately 60,000 cases leading to 13,000 deaths. Within Europe there is some geographical variation in
the incidence of melanoma, with the highest rates reported in Scandinavia (15 cases per 100,000 inhabitants per
year) and the lowest in the Mediterranean countries (5 to 7 cases per 100,000 inhabitants per year).
Methods: The present article is based on the information collected in the MELODY study (MELanoma treatment
patterns and Outcomes among patients with unresectable stage III or stage IV Disease: a retrospective longitudinal
survey).
In that study, the medical charts of patients were reviewed to document current treatment patterns and to analyse
information on patients, disease characteristics and healthcare resource utilization related to the treatment of
advanced melanoma regarding patients who presented with a diagnosis of malignant melanoma (stage I to IV) at
participating sites between 01 July, 2005 and 30 June, 2006.
Results: Summarizing, though the length of the follow-up period varies among sample patients, an amount of the
yearly cost per patient can be estimated, dividing the average per patient total cost (€ 5.040) by the average
follow-up duration (17.5 months) and reporting to one year; on these grounds, unresectable stage III or stage IV
melanoma in Italy would cost € 3,456 per patient per year.
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In recent decades, melanoma incidence has been in-
creasing in European countries; in 2006, there were ap-
proximately 60,000 cases leading to 13,000 deaths [1,2].
Within Europe there is some geographical variation in
the incidence of melanoma, with the highest rates
reported in Scandinavia (15 cases per 100,000 inhabi-
tants per year) and the lowest in the Mediterranean
countries (5 to 7 cases per 100,000 inhabitants per year)
[3,4].
Risk factors for melanoma include family history of
the disease, presence of multiple moles and a previous
melanoma [5]. Epidemiological studies have shown acute* Correspondence: mmaio@cro.it
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reproduction in any medium, provided the orand intermittent sunlight exposure is a major environ-
mental etiological factor of malignant melanoma, but
the evidence for the causative role of sunlight is still
conflicting. Physical protection from exposure to sun-
light is generally accepted as the most important factor
of melanoma risk reduction. Active public education
campaigns aimed at encouraging earlier detection of
melanoma have led to the diagnosis of thinner lesions
with a better prognosis [3,6].
Although melanoma accounts for only 4 percent of all
skin cancers, it is responsible for 80 percent of deaths
from this type of cancer and causes disproportionate
mortality in patients of young and middle age [5,6]. Esti-
mates of mortality rate from melanoma in Europe vary
between 1.5 to 5.2 per 100,000 inhabitants per year [1].
More recent improvements in survival have been
attributed in part to the earlier detection of melanoma.d. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Maio et al. Journal of Experimental & Clinical Cancer Research 2012, 31:91 Page 2 of 13
http://www.jeccr.com/content/31/1/91If the disease becomes metastatic, it is considered incur-
able. The prognosis for patients with distant metastasis
remains bleak, with an estimated median survival of 6 to
10 months and less than 5 percent of patients surviving
for more than 5 years [7].
Local recurrences of malignant melanoma and in-
transit metastasis are most effectively treated by surgical
excision. Radiotherapy to bone or skin metastases can
provide short term symptomatic control and offer pallia-
tive value, but patients in Europe with unresectable
metastatic disease have very few systemic treatment
options. Dacarbazine, an alkylating agent, is approved in
Europe for the treatment of metastatic melanoma [6,8].
A number of other agents, including temozolomide and
fotemustine, have been investigated for treatment of
metastatic melanoma and because of their ability to
cross the blood–brain barrier, may be used preferentially
in melanoma patients with brain metastasis. However,
no agent has been shown to improve survival rates. Im-
munotherapy with interleukin-2, approved by the FDA
in the United States, did not receive approval for the
treatment of metastatic melanoma in Europe. Little pro-
gress has been made in the medical treatment of meta-
static melanoma in the last 3 decades [9].
The limited number of approved treatments for
advanced melanoma patients suggests there is a high,
unmet medical need for new therapies [10,11].
Methods
In the development of new treatments, it is important to
have an understanding of existing treatment options. In
diseases such as advanced melanoma where few
approved and effective treatment options exist, clinicians
may adopt different approaches to manage patients’ dis-
ease. Documenting and characterizing current treat-
ments and their associated cost is important to define
the dominant treatment practice and to quantify the im-
pact of existing therapeutic strategies in terms of both
clinical benefit for the patient, as well as cost to the
healthcare system. Consequently the primary objective
of this study is to document treatment patterns and
evaluate relevant costs. In particular, to document first-
line, second-line and beyond treatments types as well as
the frequency with which they are used in patients diag-
nosed with unresectable stage III or stage IV melanoma.
The present article is based on the information col-
lected in the MELODY study (MELanoma treatment
patterns and Outcomes among patients with unresect-
able stage III or stage IV Disease: a retrospective longitu-
dinal surveY).
In that study, the medical charts of patients were
reviewed to document current treatment patterns and
to analyse information on patients, disease characteris-
tics and healthcare resource utilization related to thetreatment of advanced melanoma. Moreover, the perspec-
tive of the Italian National Health System is adopted, so
only direct costs are considered.
The MELODY study
The MELODY study was conducted as a multinatio-
nal, observational retrospective longitudinal survey of
patients diagnosed with unresectable stage III or stage
IV melanoma. The target sample population was ap-
proximately 750 patients from 3 European countries:
France, Italy and the United Kingdom. In each country
10 sites were selected, providing approximately 250
patients per country. In each participating site, consecu-
tive patients with a diagnosis of malignant melanoma
(stage III to IV) who presented at the site between 01
July 2005 and 30 June 2006 were entered into a registry
where a limited set of parameters related to date and
stage of disease was captured. Staging was in accordance
with the American Joint Commission on Cancer (AJCC
2001) criteria [12]. Each site entered patients into the
registry up to a maximum of 250 patients or until 25 eli-
gible patients (those with a diagnosis of unresectable
stage III or stage IV melanoma) were identified (which-
ever occurred first).
For each patient who met all inclusion criteria, med-
ical chart data were abstracted beginning from the date
of unresectable stage III or stage IV diagnosis until 01
May, 2008 or death, whichever occurred first. Given an
estimated median survival of 6 to 10 months in the pa-
tient population, the duration of the follow-up from
diagnosis until 01 May 2008 allowed an adequate time
to collect information on treatments received, patient
and disease characteristics, and health resource utiliza-
tion. The patient identity (name, address and other iden-
tifiers) was not collected and ethics committee approval
and patient informed consent were obtained.
Treatment data were collected by line of therapy. Data
included systemic therapy (chemotherapy, immunother-
apy), surgery, radiation, supportive care only, enrolment
in a clinical trial or no treatment. For systemic therapy,
name of the drug, schedule and method of administra-
tion, duration of treatment and reason for stopping
treatment were collected. If a patient was enrolled in a
clinical trial for treatment of advanced melanoma, the
duration of the participation in the trial was noted in the
case report form, but no further details (name of drug,
schedule of administration) were collected.
Healthcare resource utilization
Categories of healthcare resource utilization included
hospitalizations, outpatient visits, emergency department
visits, hospice care, surgery, radiotherapy and manage-
ment of adverse events (transfusions and concomitant
medications including antiemetics and growth factors)
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IV melanoma. Resource use related to treatments
received as a part of a clinical trial was not reported.
In the MELODY study data were also collected on
clinical benefits and outcomes of the treatments (re-
sponse rate, disease control rate, time to response, dur-
ation of response and progression free survival). In this
article only the response rate has been considered, in
order to evaluate the level of costs per patient respect-
ively responsive and non responsive to systemic therapy,
stratifying by line and type of treatment.
Due to the anticipated small proportion of patients
who receive second-line treatment and beyond, later
lines of treatment were not characterized with the same
level of precision as first-line treatments, hence caution
should be applied in the interpretation of the findings
regarding those lines. Loss to follow-up (including
patients who stop treatment prematurely, transfer out of
the treatment facility or death not documented in the
patient’s medical chart) is an inherent limitation of any
retrospective study design. However, due to the short
median duration of survival and to the frequent contacts
between clinicians treating patients with advanced dis-
ease, loss to follow-up was low. For this reason, without
compromising the sample size, only patients having a
follow-up of ≥ 2 months were included in the study, in
order to minimize the number of patients whose melan-
oma was not treated or for whom no information on
treatment was available.Figure 1 Summary of potential patient pathways through treatmentDatabase methodology and statistical analysis
Patient and disease characteristics include patient age,
gender, date and disease stage at first melanoma diagno-
sis, date and disease stage at advanced (stage III unre-
sectable or stage IV) melanoma diagnosis (according to
AJCC 2001 criteria) [12].
For each line of treatment (excluding treatments
received as a part of a clinical trial), the number and dur-
ation of hospitalizations, the duration of hospice care, the
number of outpatient visits and the number of emergency
room visits related to the treatment of unresectable stage
III or stage IV melanoma were recorded. Resource use
associated with common adverse events (transfusion, ad-
ministration of concomitant medications including anti-
emetics and growth factors) was recorded too.
Statistical analyses are predominantly descriptive in
nature, presented as summary tables and including cal-
culation of measures of central tendency and standard
deviations for continuous variables and frequency distri-
butions for categorical variables. The following analyses
were performed on the sample data relative to the Italian
patients.
MELODY study: the Italian sub-study
Stratification variables
The population of interest included all patients in the
participating Italian sites diagnosed with unresectable
stage III or stage IV melanoma who received active
treatment with systemic therapy, outside of a clinicaland health states in the MELODY study.
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this population varied across therapy lines, as shown in
Figure 1. Up to three lines of active therapy were
recorded per patient but, at any point of the treatment,
disease progression might occur and some patients re-
turn to a subsequent line of active therapy following
progression. From active therapy or progression, patients
might move to supportive care, with the assumption
of no return to active therapy following start of sup-
portive care.
Within each line of therapy, all resource utilization
variables were recorded for eligible patients receiving
systemic therapy. Surgeries and radiotherapy were also
recorded for patients receiving these therapies in com-
bination with systemic therapy. If a patient switched
from active therapy to supportive care, a subset of
resource utilization variables were recorded (hospital-
ization, outpatient, emergency room, hospice care).
Within each line of active therapy, response was classi-
fied into five levels: complete response, partial response,
stable disease, no response, and unable to determine.
For the cost analyses at the therapy line level, differentTable 1 Treatment of advanced melanoma in Italy - Unit cost
Resource use item Unit Cost (€
Hospitalization cost per day 740
Hospice stay cost per day 211
Emergency room visit cost per visit 252
Outpatient (specialist visit) cost per visit 22
Adverse events (AE) cost per day see No
Radiotherapy cost per regimen in combination
with systemic therapy
2814
Transfusion cost per procedure 179
SURGERY
Resection of primary tumor cost per procedure 2785
Lymph node resection cost per procedure 1359
All other visceral cost per procedure 7322
Brain metastases cost per procedure 13493
Isolated limb perfusion cost per procedure 2411
Biopsy cost per procedure 14
Distant skin cost per procedure 2072
Lung cost per procedure 8335response status were grouped into two levels: any re-
sponse (complete, partial, or stable disease) vs. no docu-
mented response (no response or unable to determine).
For the cost analysis at the overall level, patients were
classified as having any response if they had a documen-
ted response to any line of therapy, vs. no response if
they did not have a documented response to any line of
therapy.
Patient follow-up time was reported and used in calcu-
lating outcomes per unit time. Follow-up time was con-
sidered both overall and within lines of treatment and
was calculated as follows:
- Overall follow-up time was defined as the length of
time between first date of active therapy and last active
date, where last active date is defined to be the date of
last contact, death date, or censor date as appropriate
for each patient.
- Follow-up time on a line of active therapy was
defined as the difference between start date of the ther-
apy and start date of next therapy for patients who went
on to receive further active therapy or supportive care,
or the difference between therapy start date and lasts
2009) Notes Source
Cost for one day stay in hospital, overall average.
Original data referred to 2004, inflated to
2009 via consumer price index
[13]
Daily current tariff, mean of Lombardy
and Piedmont values
[14]
Original cost data referred to 2007,
inflated to 2009 via consumer price index
[15]
Specialist visit, current tariff (code: 89.7) [16]
te AEs classified into categories based on
ATC coding (level 2) of the drugs used
for their treatment. Daily drug cost based
on most frequently prescribed medications
(e.g. ondansetron, filgrastim, lenograstim,
pegfilgrastim, etc.)
[17]
DRG 409 (radiotherapy in day hospital)
current tariff times average
radiotherapies/patient number (7.5)
[18,19]
Current tariff for one unit (ml 280 +/− 20%)
of red blood cells added to transfusion
procedure tariff (code: 99.07.1)
[16,20]
DRG 266 tariff
DRG 270 tariff [18]
Average of DRG tariffs (192: liver
and pancreas; 149: abdomen; 303: kidney)
[18]
DRG 001 tariff [18]
DRG 273 tariff [18]
Procedure tariff (code: 86.11) [16]
Average of DRG 266 and 270 tariffs [18]
DRG 75 tariff [18]
Table 2 Descriptive statistics of study sample
Italy population (N = 215)

























Supportive care 4,9 5
Received supportive care N %
Total 24 11,2%
with at least one line of
active systematic therapy
17 7,9%
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therapy.
Sample profile
The total number of patients was stratified in three lines
of active therapy plus supportive care. At the end of the
follow-up, the same patient might have been included in
more than one line of therapy (due to successively mov-
ing from one to another).
Outcome variables stratification
All outcomes relating to intensity of resource utilization
were stratified by line of therapy and by response rate.
Due to low outcome rates, for hospice care, emergency
room visits and transfusion, no stratification was consid-
ered. For adverse events the only stratification consid-
ered was per line of therapy, as response status is not of
interest with respect to adverse events. Medication use
was adopted as a proxy for adverse events incidence and
duration.
Italian unit costs
Table 1 shows unit costs for Italy in 2009 euro values.
Unit costs were obtained from several sources (when
available, from published microcosting analysis or from
published articles). When real costs were not available,
current tariffs (mainly DRG ones) were used as a proxy.
The costs of medical management agents for adverse
events were calculated using an algorithm where adverse
events were classified into categories based on ATC
(Anatomical Therapeutic Chemical - level 2) of the
drugs used for their treatment. Daily drug cost was
based on most frequently prescribed medication. When
necessary, original cost data were inflated to 2009 via
consumer price index. More detailed information on
unit cost can be found on notes included in Table 1, and
in relevant references there quoted.
Results
Characteristics of the study sample
Table 2 reports descriptive statistics of the sub-study
sample. The sample included 215 patients, who were eli-
gible to contribute resource utilization data having
received active therapy only (191), active therapy and
supportive care (17) and supportive care without prior
resource utilization (7). Moreover, 147 received first- line
therapy, 112 second-line therapy and 41 third-line ther-
apy (Figure 2). Stratification per line of active therapy
considered 300 therapeutic treatments, a larger number
than the total of patients receiving active therapy (208),
because the same patient might have received more than
one line of therapy.
The different major therapy options used are: 33% first
line patients were treated with dacarbazine, 20% withfotemustine, and 12% with a combination of dacarbazine
+fotemustine; in second line, 51% of patients were trea-
ted with fotemustine, and 10% with dacarbazine; in third
line, fotemustine was used for 40% of patients, while
dacarbazine for 8% of patients.
The mean age at the diagnosis was 55 years and male
patients represented 62.9% of the sample. Among the
300 therapeutic treatments 42.8% showed some response
to systemic therapy. Within each line of therapy – that
is net of double counting – response rate was lower
(36.1% in the first line, 30.4% in the second line and 34.1
in the third line).
The total length of follow-up time was 17.5 months,
with lower durations in the first line (9.9 months) in the
second line (8.9 months) and in the third line (4.9
months).
Hospitalization
Hospitalizations were not particularly frequent, with less
than 10% of all patients experiencing it. Hospitalization
tended to be more frequent (12.4% vs 5.9%) for patients
Figure 2 Sample sizes of individuals eligible to contribute resource utilization data during active therapy and supportive care in Italy.
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with those with no response (Table 3, Table 4 and
Table 5). Hospitalization was the most expensive cat-
egory of resource utilisation, both among those who
experienced hospitalization (mean total cost of € 25,540)
and with reference to the generality of the sample (i.e.
including patients with zero utilisation): € 2,481. More-
over, the mean cost per patient with any response to sys-
temic therapy was higher than the mean cost per patientTable 3 Summary statistics for hospitalizations for patients re
Overall
N 215
Patients with any hospitalization N 21
% 9,8%
Total length of hospitalization (days) Mean 34,3
95%CI 0-73,7
Length of hospitalization (days/month(1)) Mean 1,9
95%CI 0,6-3,2
Total hospitalization cost




per hospitalized patient per month (€ 2009)
Mean 1.400
95% CI 400-2.400
Total hospitalization cost per patient (€ 2009) Mean 2.481
(1) month of follow-up.with no response (€ 4,524 vs € 882); the mean cost per
patient in the first line of therapy (€ 2,634) was higher
than the overall cost (€ 2,481), and much higher than
the mean cost per patient in the second (€ 588) and
third (€1.356) line of therapy.
As previously pointed out, the same patient might be
included in more than one sub-set (first-line, second-
line and third-line). But this event raises perplexities







147 112 41 24
11 7 4 4
7,5% 6,3% 9,8% 16,7%
47,5 12,7 18,8 8,2
0-126,6 6,6-18,8 0-38,9 1,1-15,4
11,6 6,1 7,5 19,8
0-30,8 0-15,3 0-27,4 0-74,2
35.200 9.400 13.900 6.100
0-93.700 4.900-13.900 0-28.800 800-11.400
8.600 4.500 5.600 14.700
0-22.800 0-11.300 0-20.300 0-54.900
2.634 588 1.356 1.017
Table 4 Summary statistics for hospitalizations for patients with any response to systemic therapy
Overall First-line therapy Second-line therapy Third-line therapy
N 89 53 34 14
Patients with any hospitalization N 11 5 4 1
% 12,4% 9,4% 11,8% 7,1%
Total length of hospitalization (days) Mean 49,5 13,4 10,5 16
95% CI 0-129,9 2,2-24,6 0,6-20,4 NA
Length of hospitalization (days/month(1)) Mean 3 3,3 1,2 1,4
95%CI 1,4-4,6 0,9-5,8 0,6-1,8 1,4-1,4
Total hospitalization cost
per hospitalized patient (€ 2009)
Mean 36.600 9.900 7.770 11.800
95% CI 0-96.100 1.600-18.200 400-15.100 NA
Total hospitalization cost
per hospitalized patient per month (€ 2009)
Mean 2.200 2.400 888 1.000
95% CI 1.000-3.400 700-4.300 400-1.300 1.000-1.000
Total hospitalization cost per patient (€ 2009) Mean 4.524 934 914 843
(1) month of follow-up.
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for patients with any response to systemic therapy and
with no response to systemic therapy (Tables 4 and
Table 5). For example, the overall mean length of stay
does not correspond to the mean of the line-specific
length of stay in Table 4 (“Any response to therapy”).
This is due to the definition of responders. Within each
line of therapy, patients are classified as responders or
non-responders, and their results are included in the
corresponding table. For the Overall column, a patient is
included in the “Any Response” table if he/she did ever
respond to a single line of therapy, and is included in
the “No Response” table if he/she never did. So, consid-
ering a hypothetical patient who responded to first-line
therapy but not to second-line or third-line therapy, he
would be included in the Overall column and in the
first-line column in Table 4 (since he did respond to this
line of therapy); and he would be included in the
second- and third-line columns in Table 5 (because he
did not respond to these lines of therapy). ConsequentlyTable 5 Summary statistics for hospitalizations for patients w
Overall
N 119
Patients with any hospitalization N 7
% 5,9%
Total length of hospitalization (days) Mean 20,3
95% CI 10,5-30,1
Length of hospitalization (days/month(1)) Mean 2,5
95%CI 1,9-3
Total hospitalization cost




per hospitalized patient per month (€ 2009)
Mean 1.900
95% CI 1.400-2.200
Total hospitalization cost per patient (€ 2009) Mean 882
(1) month of follow-up.Overall columns in Table 4 (and analogously in Table 5)
do not correspond to an average of the line-specific col-
umns because patients can move across tablesa.
These methodological considerations are done here to
justify why results will not be commented separately per
single line of treatment, when patients are analyzed with
any/no response to systemic therapy.
Summarizing, though the length of the follow-up
period varies among sample patients, an amount of the
yearly cost per patient can be estimated, dividing the
average per patient total cost (€ 5.040) by the average
follow-up duration (17.5 months) and reporting to one
year; on these grounds, unresectable stage III or stage IV
melanoma in Italy would cost € 3,456 per patient
per year.Hospice care
Approximately 6% of patients received hospice care with
a mean cost per admitted patient of € 3.300. Due to theith no response to systemic therapy













Table 6 Summary statistics for outpatient visits for patients receiving systemic therapy and/or supportive care
Overall First-line therapy Second-line therapy Third-line therapy Supportive care
N 215 147 112 41 24
Patients with any outpatient visits N 87 44 36 19 15
% 40,5% 29,9% 32,1% 46,3% 62,5%
Total number of outpatient visits
per visited patient
Mean 3,3 2,4 2,5 2,5 2,7
95%CI 2,8-3,7 2,1-2,8 2-3 1,8-3,2 1,9-3,4
Total number of outpatient visits
per visited patient per month (1)
Mean 0,3 0,5 0,6 0,5 3,3
95%CI 0,2-0,4 0,3-0,7 0,3-0,9 0,4-0,7 0-7,1
Total outpatient cost
per visited patient (€ 2009)
Mean 70 50 60 50 60
95% CI 60-80 50-60 40-70 40-70 40-80
Total outpatient cost
per visited patient per month (€ 2009)
Mean 7 11 13 11 73
95% CI 4-9 7-15 7-20 9-15 0-156
Total outpatient cost per patient (€ 2009) Mean 28 15 19 23 38
(1) month of follow-up.
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the generality of the sample is quite low (€ 184).Emergency room visit
Emergency room visits were very rare: overall 1.4% of
patients had one or more visit. Consequently the mean
cost for the generality of the sample is very low (€ 4).Outpatient visit
Outpatient visits were the most common category of re-
source utilization: 40.5% of patients had at least one
visit, with 3.3 visits per patient (Overall) on average. As
compared with other major categories of utilization, out-
patient visits were relatively inexpensive, with a mean
cost of € 70 per visited patient and a mean cost for the
generality of the sample of € 28 (Table 6). Outpatient
visits were more frequent in patients with any response
to systemic therapy, where the mean cost per patientTable 7 Cost of adverse event management for most common






Antiemetics and antinauseants Ondansetron (1), (2) 90,7
Drugs for acid related disorders Omeprazole 75






Immunostimulants Filgrastim (3) 44,4
Lenograstim 11,1
Pegfilgrastim (4) 11,1
(1) Assumed maximum duration 3 days per 21-day cycle throughout observed mean
(2) Unit cost is per day, given once per 21-day cycle throughout observed mean dur
(3) Assumed maximum duration 12 days; if observed mean duration of 23,2 days is
(4) Unit cost is per cycle, given once per 21-day cycle throughout observed mean dwas higher than the mean cost per non responder pa-
tient (€ 33 vs € 22).
Adverse events
On the whole, 24% of patients received medications to
manage one or more adverse events (AE). Most of the
patients experienced just one AE requiring medical
management. The most frequent category of AE medical
management agent was antiemetics and antinauseants,
the most expensive category of medication was immu-
nostimulants, ranging from € 785 to € 3,051 per episode
(Table 7).
Radiotherapy
Among patients who received systemic therapy, 19.7%
received radiotherapy in combination (Tables 8 and 9).
Radiotherapy costs were based on standard protocols
regimens. Mean cost per patient receiving radiotherapy
was equal to the unit cost of this resource (€ 2.814).ly prescribed agents (occurring in ≥ 5% of patients
events
ent

















used, then total cost is 1517,7.
uration.
Table 8 Summary statistics for radiotherapy for patients receiving systemic therapy
Overall First-line therapy Second-line therapy Third-line therapy
N 208 147 112 41
Patients with any radiotherapy N 41 24 13 6
% 19,7% 16,3% 11,6% 14,6%
Incidence of radiotherapy
(per patient with any radiotherapy per month (1))
Mean 0,1 0,31 0,27 0,14
95% CI 0,08-0,13 0,13-0,5 0,07-0,46 0,03-0,24
Total radiotherapy cost
per patient with any radiotherapy (€ 2009)
Mean 2.814 2.814 2.814 2.814
Total radiotherapy cost
per patient with any radiotherapy per month (€ 2009)
Mean 300 900 800 400
95% CI 200-400 400-1.400 200-1.300 100-700
Total radiotherapy cost per patient (€ 2009) Mean 555 459 327 412
(1) month of follow-up.
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resulted equal to € 555. Small differences in mean cost
per patient with any response (€ 506) vs no response
(€591) are due to the different frequency in the resource
use (18.05% vs 21%).
Transfusion
Transfusions were relatively rare, with 3.8% of all
patients who received systemic therapy also receiving a
transfusion. Consequently the mean cost for the general-
ity of the sample is very low (€ 12).
Surgery
24% of patients received surgery in combination with
systemic therapy (Table 10). Surgery was more common
in patients who had any response to systemic therapy
(30.35%) as compared with those with no response
(19,3%) (Tables 11 and 12). Surgery was among the most
expensive categories of resource utilization, with a mean
cost of € 7,390 per patient with any surgery. With refer-
ence to the generality of the sample, mean cost per
patient with any response was equal to € 2,312, which
is higher than the cost per patient with no response
(€ 1.376).Table 9 Summary statistics for radiotherapy for patients with
Overall
N 89
Patients with any radiotherapy N 16
% 18,0%
Incidence of radiotherapy




per patient with any radiotherapy (€ 2009)
Mean 2.814
Total radiotherapy cost
per patient with any radiotherapy per month (€ 2009)
Mean 200
95% CI 100-200
Total radiotherapy cost per patient (€ 2009) Mean 506
(1) month of follow-up.Conclusions
In the MELODY study data on resource use is collected
based on patients stratification accordingly to treatment
line, which implies that a given patient may be included
in more than one line. This is the reason why in the
present article costs per line are not examined, since the
balancing cannot be found between the mean cost of
the whole sample and the weighted mean cost of the
strata. Instead, (Overall) costs are considered within two
strata (patients with any/no response to systemic ther-
apy) since the number of patients considered therein is
stable within the different cost categories, so that the
weighted mean cost of the two strata approximates the
mean cost of the whole sample.
Moreover, it has to be noted that the reference period
for calculating resource consumption by each patient
corresponds to the follow-up period, which varies among
patients. Therefore, the mean cost per patient is not dir-
ectly referred to a standard time period (e.g. one year).
The following summary data must be appraised in the
light of the above considerations, bearing in mind that
the follow-up period is 17.5 months long on the average
(Table 2) and that the balancing is rough between the
mean cost of the whole sample and the weighted meanany response to systemic therapy










Table 10 Summary statistics for surgery for patients receiving systemic therapy
Overall First-line therapy Second-line therapy Third-line therapy
N 208 147 112 41
Patients with any surgery N 50 36 18 5
% 24,0% 24,5% 16,1% 12,2%
Type of surgery
Resection of primary tumor % 9% 9% 0% 0%
Lymph node resection % 21% 16% 3% 2%
All other visceral % 22% 12% 7% 3%
Brain metastases % 9% 5% 3% 1%
Isolated limb perfusion % 0% 0% 0% 0%
Biopsy % 12% 9% 2% 1%
Distant skin, subcutaneous or node % 12% 9% 3% 0%
Lung % 1% 1% 0% 0%
Total surgery cost
per patient with any surgery (€ 2009)
Mean 7.390 6.368 5.670 7.638
Total surgery cost per patient (€ 2009) Mean 1.776 1.560 911 931
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(Table 13).
The mean cost per patient for the generality of the
sample is € 5,040. Hospitalisation is responsible for one
half (49.2%) of it and surgery for more than one third
(35.2%), so that both categories take up about 85% of the
total amount. Radiotherapy is the third relevant category
(10%). Of the remaining ones, only hospice is non
negligible.
On the whole, these resources are supplied in a spe-
cialistic environment, for which hospitalization of pa-
tient is required. Only visits can be performed in
outpatient setting.
The cost composition is emphasized in the former of
the two strata considered (patients with any response toTable 11 Summary statistics for surgery for patients with any
Overal
N 89
Patients with any surgery N 27
% 30,3%
Type of surgery
Resection of primary tumor % 6%
Lymph node resection % 11%
All other visceral % 12%
Brain metastases % 5%
Isolated limb perfusion % 0%
Biopsy % 6%
Distant skin, subcutaneous or node % 5%
Lung % 1%
Total surgery cost per patient with any surgery (€ 2009) Mean 7.621
Total surgery cost per patient (€ 2009) Mean 2.312systemic therapy): hospitalization (59.7%) and surgery
(30.5%) take up more than 90% of the cost for resources.
Among patients with no response, instead, both categor-
ies together take up only 73.5%, where – on the other
hand – hospitalization decreases to 28.7% but surgery
increases to 44%; in this stratum the share for radiother-
apy too is high (19.2%), when compared with the analo-
gous in the former stratum (6.7%). Considering, moreover,
that patients with any response cost on the average two
and a half times compared to patients with no response
(€ 7,575 vs € 3,071), one can infer that treatment pro-
files are remarkably different: in the former stratum
hospitalization (where chemotherapy is administered) is
prevailing, while in the latter surgery and radiotherapy
come first.response to systemic therapy














Table 12 Summary statistics for surgery for patients with no response to systemic therapy
Overall First-line therapy Second-line therapy Third-line therapy
N 119 94 78 27
Patients with any surgery N 23 23 10 3
% 19,3% 24,5% 12,8% 11,1%
Type of surgery
Resection of primary tumor % 3% 3% 0% 0%
Lymph node resection % 10% 9% 2% 1%
All other visceral % 10% 7% 3% 3%
Brain metastases % 4% 2% 2% 0%
Isolated limb perfusion % 0% 0% 0% 0%
Biopsy % 6% 6% 1% 1%
Distant skin, subcutaneous or node % 7% 6% 2% 0%
Lung % 0% 0% 0% 0%
Total surgery cost per patient with any surgery (€ 2009) Mean 7.119 4.841 5.583 7.780
Total surgery cost per patient (€ 2009) Mean 1.376 1.185 716 864
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first study where the cost of treatment for a patient with
advanced melanoma has been estimated in Italy. Even at
the international level, few cost of illness studies can be
found reporting such data. Some of such studies do ana-
lyse cost as a function of the illness stage; nevertheless,
due to differences in methods, their results cannot be
compared with the findings of the present study. More-
over, such studies are generally focused on the total cost
charged to the national health system, from which they
cannot derive a per patient cost based on of epidemio-
logical information.
However, a study carried out in Spain reports cost data
at patient level (referred to 2007) [21]. Based on a theor-
etical model, it concludes that higher costs are associated
to patients with advanced melanoma. Only direct med-
ical costs were considered, particularly hospitalization









Hospitalization 9,8% 25.400 2.481
Hospice 5,6% 3.300 184
Emergency room 1,4% 300 4
Outpatient 40,5% 70 28
Radiotherapy 19,7% 2.814 555
Transfusion 3,8% 300 12
Surgery 24% 7.390 1.776
Total 5.0470
(1) For the follow-up period (17,5 months on average). Patients with zero resource u
(2) For patients with any response to systemic therapy.
(3) For patients with no response to systemic therapy.
(4) Overall data as a proxy.illness: detection, resection, surgical treatment of lymph-
atic spread, oncologic treatment of metastatic melanoma.
As a first approximation, patients included in the fourth
level might be considered homogeneous with those en-
rolled in the MELODY study. In the Spanish study two
average per patient cost data (on yearly basis) are
reported with reference to advanced melanoma: for
patients with lymph node metastasis (€ 6,457) and for
patients with visceral metastasis (€ 1,036). Size informa-
tion of the two subset is not provided, so a weighted
average cannot be calculated. But, assuming approxi-
mately equal sizes, an average value would result similar
to that above reported for Italy (€ 3,456).
For the sake of completeness it is worthwhile reporting
the results from three further studies, though no per pa-
tient cost data are there provided. In the first study,
which is referred to France, the yearly (2004) cost is esti-





based on mean (1), (2) (€)
Overall cost
per non-responder
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http://www.jeccr.com/content/31/1/91with melanoma [22]. Such cost amounts to € 59 million,
27 (45%) of which are born for patients with metastasis.
Main cost drivers are surgery (38%), follow-up evalua-
tions (20%) and chemotherapy (17%). Authors conclude
that costs for treating melanoma represent less than 1%
of total French hospital system costs for cancer.
In the second and third study, the cost of melanoma
was evaluated within a larger research focused on costs
of all kinds of skin tumours. In particular, in the second
study [23] cost data (2003) are reported relative to the
hospital system in Germany, where about 20% of hospi-
talizations for skin tumours (62,384) are related to
patients with melanoma (20,445), identified with ICD 10
code C43. For such patients, the total cost estimate vary
depending on the resource evaluation method adopted:
from € 59 million (evaluation with DRG tariffs) to € 55
million (evaluation with average cost per day stay). So,
the average hospitalization cost per (C43) patient ap-
proximately ranges between € 2,900 and € 2,700.
In the third study cost data (2005) are reported for
treating patients (here too identified with ICD 10 code
C43) with skin tumours in Sweden [24]. The study,
which estimated both direct and indirect costs, reports a
total amount of € 142 million, of which direct medical
costs represent 56%. Melanoma is associated to the
highest financial burden (€ 80 million, of which 22 for
direct costs). Dividing such total direct cost by the num-
ber of recorded treatment cases, an average cost per case
is obtained of about € 2,000. Considering that for each
patient more than one case on the average was recorded,
also this data may be comparable with previously
reported ones.
Before concluding, a recent review should be men-
tioned [25] where three cost-effectiveness studies and
two cost-utility studies of chemotherapic treatment of
metastatic melanoma were analysed. The authors con-
clude that the cost-effectiveness has not been widely
demonstrated for treatment of metastatic melanoma and
that a need exists for effective treatments that improve
duration and quality of life.
As a conclusive remark, a message can be drawn from
the present study: the cost for treating advanced melan-
oma is not particularly high (neither in Italy nor in other
West European countries). In our opinion, this is mainly
due to the fact that there are no effective treatmentsa-
vailable, which can improve both duration and quality of
life. Evidence of such opinion can be found in the low
frequencies with which some resources are used, in par-
ticular hospitalization (less than 10%), considering that
patients are hospitalized mainly for being administered
an antitumoral therapy. Further evidence is provided by
the above mentioned review [25], showing the poor
cost-effectiveness of the analyzed treatments. Also the
French study [22] confirms the low financial impact ofthe advanced melanoma treatment (less than 1% of total
French hospital system costs for cancer). A medical need
does therefore exist (as pointed out in most studies
here considered) of more research and development
investments in new effective and safe pharmacological
treatments.
Endnotes
aThis is true for all the tables focused on response/non-
response to therapy (i.e. tables regarding hospitalization,
outpatient visits, radiotherapy, surgery), although it is
most noticeable for hospitalization length of stay because
this is an outcome that can be heavily influenced by a sin-
gle patient with a long hospitalization. For example, if a
patient had a very long hospitalization during first line
therapy, and he did not respond to first-line therapy but
did to a subsequent line of therapy, such hospitalization
would be included in the Overall column in Table 4
(because the patient did respond to at least one line of
therapy), and in the first-line column in Table 5 (because
he did not respond to first-line therapy, which is when the
hospitalization actually took place).
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